# A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies

> **NCT00730639** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 395 (actual)

## Conditions studied

- Metastatic Castration-resistant Prostrate Cancer
- Renal Cell Carcinoma
- Metastatic Melanoma
- Non-small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** BMS-936558 (MDX-1106)
- **BIOLOGICAL:** BMS-936558 (MDX-1106)
- **BIOLOGICAL:** BMS-936558 (MDX-1106)
- **BIOLOGICAL:** BMS-936558 (MDX-1106)
- **BIOLOGICAL:** BMS-936558 (MDX-1106)

## Key facts

- **NCT ID:** NCT00730639
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10-30
- **Primary completion:** 2013-02-04
- **Final completion:** 2020-12-22
- **Target enrollment:** 395 (ACTUAL)
- **Last updated:** 2021-12-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00730639

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00730639, "A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00730639. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*